Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Jan-Feb;10(1):13-24.
doi: 10.1310/hct1001-13.

Access to medications and medical care after participation in HIV clinical trials: a systematic review of trial protocols and informed consent documents

Andrea L Ciaranello  1 , Rochelle P Walensky, Paul E Sax, Yuchiao Chang, Kenneth A Freedberg, Joel S Weissman
Affiliations

Access to medications and medical care after participation in HIV clinical trials: a systematic review of trial protocols and informed consent documents

Andrea L Ciaranello et al. HIV Clin Trials. 2009 Jan-Feb.

Abstract

Background: Expectations regarding receipt of medications and medical care after clinical trials conclude may inform decisions about trial participation. We describe the frequency with which these posttrial services are described in the protocols and informed consent forms (ICFs) of antiretroviral drug (ARV) trials.

Method: We systematically reviewed protocols and ICFs from Phase 3 and 4 antiretroviral trials in adults (> or = 12 years) from 1987 to 2006. Pharmaceutical industry-sponsored trials were selected from US Food and Drug Administration (FDA) documentation and Clinicaltrials.gov. Trials administered by the AIDS Clinical Trials Group (ACTG) were selected from the ACTG online registry. ACTG- and industry-provided protocols and ICFs were reviewed in full. The primary outcome was any mention of posttrial services, defined as any text regarding posttrial medications or medical care.

Results: Complete trial documents were available for 31 (48%) of 65 trials meeting inclusion criteria. Documents from 14 trials (45%) mentioned any posttrial service: 12 (39%) mentioned medications, and 5 (16%) mentioned medical care. Payment for trial participation (74%) and for care for trial-related injury (94%) were mentioned more often than were posttrial services.

Conclusions: Posttrial medications or medical care was mentioned in the trial documents of <50% of reviewed antiretroviral trials. Improved efforts are needed to clearly describe posttrial services in clinical trial protocols and ICFs.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: Paul E. Sax reports serving as a consultant for Abbott, BMS, Gilead, Glaxo-SmithKline, Merck, and Tibotec; receiving teaching honoraria from Abbott, BMS, Gilead, Merck, and Tibotec; and receiving grant support from Tibotec and Merck. Other authors have no conflicts of interest to disclose.

References

    1. Pace C, Grady C, Wendler D, Bebchuk JD, Tavel JA, McNay LA, et al. Post-trial access to tested interventions: The views of IRB/REC chair, investigators, and research participants in a multinational HIV/AIDS study. AIDS Res Hum Retroviruses. 2006;22:837–841. - PubMed
    1. Moral standards for research in developing countries: From “reasonable availability” to “fair benefi ts.”. Hastings Center Report; Participants in the 2001 Conference on Ethical Aspects of Research in Developing Countries.2004. pp. 17–27. - PubMed
    1. Emanuel EJ. Undue inducement: Nonsense on stilts? Am J Bioethics. 2005;5:9–13. - PubMed
    1. GlaxoSmithKline. Clinical trials in the developing world. 2005. [Accessed December 15, 2005]. Available at: http://www.gsk.com/corporate_responsibility/Downloads/clinical_trials_in....
    1. Macklin R. After Helsinki: Unresolved issues in international research. Kennedy Inst Ethics J. 2001;11:17–36. - PubMed

Publication types

Substances